期刊文献+

39例妊娠相关乳腺癌的病理特征及分子分型 被引量:2

Analysis of clinicopathological features and molecular subtypes in 39 cases of pregnancy associated breast cancer
原文传递
导出
摘要 目的探讨妊娠相关乳腺癌的临床病理特征及分子分型,为妊娠相关乳腺癌的诊治提供依据。方法对39例妊娠相关乳腺癌及同期143例非妊娠相关乳腺癌患者(<45岁)的临床病理资料进行回顾性分析,采用免疫组化技术检测患者手术标本的雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER-2)、Ki-67的表达情况,并对HER-2 2+的标本进行FISH检测,根据结果进行分子分型,对比分析两组患者的临床病理特征及分子分型。结果妊娠相关乳腺癌的病理类型以浸润性导管癌为主,约占84.6%(33/39)。与同期非妊娠相关乳腺癌患者(<45岁)相比,妊娠相关乳腺癌患者临床分期和淋巴结转移率更高,差异均有统计学意义(P<0.05);所占比例Luminal B型较高,Luminal A型较低,差异有统计学意义(P<0.05)。而两组患者的病理类型、肿瘤大小、组织学分级及ER、PR、HER-2、Ki-67表达水平的差异均无统计学意义(P>0.05)。结论妊娠相关乳腺癌在确诊时临床分期晚,淋巴结转移率高,分子分型以Luminal B型为主,恶性程度高,应重视该病的早期诊治。 Objective To investigate the clinicopathological characteristics and molecular subtypes of pregnancy-associatedbreast cancer(PABC) and provide evidence for the diagnosis and treatment of PABC.Methods The clinical andpathological data of 39 cases of PABC and 143 cases of non-PABC(45 years)admitted to our hospital were reviewed.Theexpression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor 2(HER-2)and Ki-67 were detected by immunohistochemistry.The HER-2 2+ specimens were detected by FISH.The molecular subtypes wereperformed according to the results.The clinicopathological features and molecular subtypes were compared between the twogroups.Results The pathological types of PABC were mainly invasive ductal carcinoma,accounting for 84.6%(33/39).Compared with non-PABC(45 years)patients,the PABC patients had more advance clinical stage and higher lymph nodemetastasis rate(P〈0.05),and the proportion of Luminal B was higher,while Luminal A type accounted for a lowerproportion;the difference was statistically significant(P〈0.05).The pathological types,tumor size,histological grade and theexpression levels of ER,PR,HER-2 and Ki-67 in two groups had no significant differences(P〈0.05).Conclusion PABChad a more advanced clinical stage and higher lymph node metastasis rate at diagnosis,and its molecular subtype was mainlyLuminal B type with great malignancy,and the early diagnosis and treatment of the disease should be emphasized.
作者 杜瑞 郜红艺 郭玉娟 陈文静 吴坤河 DU Rui;GAO Hong-yi;GUO Yu-juan;CHEN Wen-jing;WU Kun-he(Department of Pathology,Guangdong Women and Children Hospital,Guangzhou,Guangdong 511400,China)
出处 《热带医学杂志》 CAS 2018年第7期923-926,共4页 Journal of Tropical Medicine
基金 广东省医学科研基金(A008096)
关键词 乳腺癌 妊娠 雌激素受体 Breast cancer Pregnancy Estrogen receptor
  • 相关文献

参考文献4

二级参考文献37

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献1626

同被引文献9

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部